Saturday August 19th 2017

Immunology of Relapse and Remission in Multiple Sclerosis.

Authors: Steinman L Abstract Eighty percent of individuals with multiple sclerosis (MS) initially develop a clinical pattern with periodic relapses followed by remissions, called relapsing-remitting MS (RRMS). This period of fluctuating disease may last for a decade or more. Clinical relapses reflect acute inflammation in the central nervous system (CNS), composed of the brain and spinal cord. Often, different anatomic areas in the CNS are involved each time a relapse occurs, resulting in varied clinical manifestations in each instance. Relapses are nearly always followed by some degree of remission, though recovery to baseline status before the flare is often incomplete. There are nine approved drugs for treatment of RRMS. The most potent drug for inhibiting relapses, the humanize…

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Link: 

Immunology of Relapse and Remission in Multiple Sclerosis.

Leave a Comment

More from category

Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re
Researchers Co-funded by National MS Society Report on New Way to Translate Lab Findings Aimed at Re

/About-the-Society/News/Researchers-Co-funded-by-National-MS-Society-Repor [Read More]

Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS
Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS

/About-the-Society/News/Investigators-Recruiting-for-Study-of-ALKS-8700-vs [Read More]

Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS
Statement on House Oversight and Government Reform Committee Action on the Pricing Strategies for MS

/About-the-Society/News/Statement-on-House-Oversight-and-Government-Reform [Read More]

Drug blocked by regulators found to improve quality of life for MS patients
Drug blocked by regulators found to improve quality of life for MS patients

A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with [Read More]

House Dems launch MS drug pricing probe
House Dems launch MS drug pricing probe

Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of [Read More]